Nature’s smallest messengers.
What exosomes are, how they are made inside cells, what they carry, and why their source matters — explained plainly.
How an exosome is born.
Exosomes form inside the cell along the endosomal pathway and are released when a multivesicular body fuses with the cell surface.
Uptake
The plasma membrane folds inward, engulfing extracellular material and surface proteins.
Early endosome
A vesicle pinches off and matures, sorting proteins, lipids and RNA.
Multivesicular body
Inward budding forms intraluminal vesicles — the future exosomes — loaded with cargo.
Fusion
The multivesicular body docks and fuses with the plasma membrane.
Release
Exosomes (30–200 nm) travel through fluids to reach neighbouring cells.
What is inside?
A lipid bilayer sphere packages and protects cargo and shows surface molecules that steer where it goes. Explore each part.
- 1miRNAMicroRNA — small non-coding RNA that fine-tunes gene expression in recipient cells; a leading target for biomarker work.
- 2lncRNALong non-coding RNA carried in the lumen; involved in regulating transcription and RNA processing.
- 3mtDNA & extrachromosomal DNADNA fragments packaged into vesicles; used as research markers of the parent cell.
- 4ProteinsCytosolic and structural proteins, including tetraspanins commonly used as identity markers.
- 5Small metabolitesLow-molecular-weight signalling molecules travelling inside the vesicle.
- 6Lipids & lipid raftsA cholesterol- and sphingolipid-rich bilayer with raft micro-domains gives stability and steers uptake.
- 7Surface proteinsMembrane-anchored proteins that govern targeting — which cell it docks with.
- 8Surface-associated RNA & DNANucleic acids on the outer surface, distinct from the protected lumenal cargo.
Nano, in perspective.
A logarithmic scale from 1 nanometre to 100 micrometres. Values for comparison objects are approximate.
Source decides signal.
Each cellular source carries a characteristic signalling profile.
Bone marrow
Adipose tissue
Umbilical cord
Dental tissue
PDRN
Plant, stem-cell and specialty vesicles.
| Family | Size | Sources | Research focus |
|---|---|---|---|
| Plant-derived | 40–150 nm | 16 — fruit, flower, leaf, seed, root, peel, grain | Antioxidant defence, barrier, brightening, clarity |
| MSC-derived | 30–150 nm | Bone marrow, adipose, umbilical cord, dental tissue | Tissue repair, angiogenesis, immunomodulation |
| Milk · hemp seed | 30–200 nm | Cow milk (animal-derived), hemp seed (plant) | Nano-carriers, lipid nourishment, barrier repair |
| Plant PDRN | 50–1500 bp | Plant / non-animal DNA fragments | Nucleotide salvage, wound care, regenerative systems |
Five pathways we read.
Functional evaluation links vesicle cargo to the programmes it influences in recipient cells.
Renewal
Stem-cell maintenance and tissue regeneration.
Matrix
Collagen deposition, matrix remodelling and fibrosis balance.
Inflammation
Central regulator of inflammatory gene expression.
Growth
Proliferation, migration and survival signalling.
Where exosomes are being applied.
A young discipline with a wide reach. These are the main areas where vesicle science is being researched and developed worldwide.
Wound & burn care
Vesicles that support cell migration, new-vessel growth and matrix repair are among the earliest to reach clinical studies.
Lung & respiratory
Anti-inflammatory and regenerative signalling in lung disease has drawn early-phase trials.
Orthopaedics
First human applications are now appearing for joint and cartilage conditions.
Oncology & targeted delivery
Engineered vesicles carry drugs, RNA or proteins to chosen cells.
Liquid-biopsy diagnostics
Vesicle-borne RNA and proteins from blood, urine or saliva act as non-invasive biomarkers.
Dermatology & aesthetics
Plant and stem-cell vesicles for barrier, brightening, renewal and post-procedure care — where EXOMIE works today.
Programmable by nature.
Because cells make them, vesicles can carry small molecules, mRNA, siRNA, proteins and even gene-editing components — and developers can steer them by engineering the producer cell or decorating the vesicle surface after isolation.
Familiar to the body
Their natural origin means the immune system is used to meeting them, which can reduce adverse reactions compared with fully synthetic carriers.
Crossing barriers
They can cross biological barriers, including the blood–brain barrier, that challenge many synthetic nanoparticles.
Cell-type selectivity
Surface ligands can direct vesicles to chosen tissues, widening the therapeutic window.
Naïve and engineered
Naïve vesicles are used as the cells released them. Engineered vesicles are loaded or decorated in the laboratory with a payload or targeting molecule. Both start with a well-characterised vesicle.
A population, not a molecule
Yield varies with cell type, culture conditions and scale; purification needs several optimised steps; and a vesicle product is a population rather than one defined entity — which is why measurement and documentation matter so much.
Output is arithmetic.
Total vesicles equal the number of cells multiplied by the vesicles each cell makes. Good process development raises both at once while holding quality steady.
The productivity equation
Total vesicles = cells × vesicles per cell
- Seed train — expand cells from banked stock
- Growth — expand to the target number while managing cell age
- Collection — move to a low-particle, xeno-free medium and harvest for a defined window
| Lever | What it changes |
|---|---|
| Expansion speed | More cells sooner, fewer handling steps, lower contamination risk |
| Collection medium | Removes expansion-stage contaminants so particles measured are the ones produced |
| Culture format | Flasks give way to microcarrier or stirred-tank systems for far higher cell density |
| Harvest timing | Balances yield against vesicle quality attributes |
| Downstream fit | Faster, cleaner upstream improves recovery and consistency later |
Getting vesicles out of the fluid.
Isolation is where yield, purity and reproducibility are won or lost. Established laboratory methods now share the field with newer, more automated ones.
| Approach | Principle | Trade-off |
|---|---|---|
| Ultracentrifugation | Spin vesicles out by density | Established; labour-intensive, can co-pellet contaminants |
| Size-exclusion chromatography | Separate by size on a column | Gentle, good purity; limited volume per run |
| Tangential-flow filtration | Concentrate and wash across a membrane | Scalable; needs optimisation for each fluid |
| Affinity capture | Bind surface markers, then release intact vesicles | High specificity; depends on the marker and subtype |
| Automated nanofiltration | Hands-off benchtop filtration of any fluid | Standardised workflow; newer, still being benchmarked |
| Precipitation kits | Polymer-driven pelleting | Simple and quick; lower purity |
Four questions, answered with data.
Whether for research, cosmetic or regulated use, a vesicle preparation is judged on the same four things — and supply-chain controls for storage and transport matter as much as the assay.
Identity
Size, concentration, morphology and markers show what the particles are.
Purity
Particle-to-protein ratios and contaminant limits show what else is present.
Potency
A functional assay shows the vesicles do what they are meant to do.
Safety
Sterility, endotoxin, mycoplasma and residue screening show it is safe to handle.
Regulatory reality
The US FDA states that there are currently no FDA-approved exosome products, and that exosomes used to treat disease in humans are regulated as drugs or biological products requiring premarket review. The lawful route for therapeutic use in the US is a formal Investigational New Drug application. Rules differ by country, and research and cosmetic use are regulated separately. EXOMIE supplies research- and cosmetic-grade materials and products and makes no diagnostic, treatment or cure claims.
Sources: US FDA — public safety notification on exosome products · PubMed — exosomes · MISEV2023 guidelines.
The terms, in plain language.
- EV
- Extracellular vesicle — a membrane-bound nanoparticle released by cells; exosomes are a small-EV subtype.
- MSC
- Mesenchymal stem cell — a multipotent cell used as a source of regenerative vesicles.
- NTA
- Nanoparticle tracking analysis — measures particle size distribution and concentration.
- DLS
- Dynamic light scattering — mean size, polydispersity and zeta potential.
- TEM · SEM
- Transmission / scanning electron microscopy — internal structure and surface morphology.
- miRNA
- MicroRNA — small non-coding RNA that regulates gene expression.
- PDRN
- Polydeoxyribonucleotide — DNA fragments that support tissue-repair signalling.
- COA
- Certificate of Analysis — batch-specific results against specification.
- MISEV
- Minimal Information for Studies of Extracellular Vesicles — community guidelines.
- ILV
- Intraluminal vesicle — formed inside a multivesicular body and released as an exosome.
Start with the primary literature.
- Welsh JA et al. Minimal information for studies of extracellular vesicles (MISEV2023). J Extracell Vesicles 2024.
- Théry C et al. MISEV2018. J Extracell Vesicles 2018.
- Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013.
- Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem 2019.
- Dad HA et al. Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms. Mol Ther 2021.
A research question? Ask a scientist.
Research question, bulk requirement or a product for your brand — we’ll route it to the right team and reply with a clear next step.